PCMC Authorizes Massive Share Increase, Blank-Check Preferred Stock for Acquisition

summarizeSummary

PUBLIC CO MANAGEMENT CORP has filed a preliminary information statement detailing the board and majority shareholder's approval to significantly increase authorized common and preferred stock, enabling future financing and the proposed acquisition of Physicians Capital Management Corporation.

check_boxKey Events

• Massive Share Capital Increase Approved

  The Board and majority shareholder approved an amendment to increase total authorized capital to 550 million shares, consisting of 500 million common shares and 50 million preferred shares.

• Extreme Potential Dilution

  The newly authorized shares represent over 1500% potential dilution compared to the current 34.2 million outstanding common shares.

• "Blank-Check" Preferred Stock Authority Granted

  The Board is now authorized to create and issue preferred stock series with various rights and preferences without further shareholder approval.

• Enables Proposed Acquisition

  This capital structure change is intended to facilitate the non-binding Letter of Intent to acquire Physicians Capital Management Corporation, where current PCMC shareholders would own approximately 20% post-transaction.

auto_awesomeAnalysis

This PRE 14C provides the full details of the corporate action previously disclosed in a March 2, 2026 8-K. The authorization of 500 million common shares and 50 million blank-check preferred shares represents an extreme potential dilution of over 1500% for existing shareholders, given only 34.2 million common shares are currently outstanding. This move is critical for the company's stated plan to acquire Physicians Capital Management Corporation, where current PCMC shareholders are expected to own only 20% of the combined entity. The "blank-check" preferred stock authority grants the board broad power to issue new equity without further shareholder approval, which could further dilute existing common stockholders and introduce shares with superior rights. Investors should be aware of the significant dilution risk associated with these authorizations.